On June 11, 2025, Juvena Therapeutics, Inc., a clinical-stage biotechnology company pioneering tissue restorative biologics for chronic muscle and metabolic diseases, announced it has entered a global licensing and multi-target research collaboration with Eli Lilly and Company to discover, develop, and commercialize drug candidates that improve muscle health and body composition. Wilson Sonsini Goodrich & Rosati advised Juvena Therapeutics on the transaction.

Juvena will leverage JuvNET, the world’s first, fully integrated, AI-enabled screening platform for mapping the therapeutic potential of stem cell-secreted proteins, developed by Juvena. The collaboration will identify muscle targeting drug candidates from Juvena’s proprietary library of human stem-cell secreted proteins for improved body composition and muscle health.

The Wilson Sonsini team that advised Juvena included Ian Edvalson, Nguyen Pham, Matt Bresnahan, and Scott May.

For more information, please see Juvena’s press release. Additional coverage can be found on Fierce Biotech.